3 results
Approved WMOPending
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Approved WMOPending
To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 2.0 mg aflibercept, in participants with neovascular AMD.
Approved WMOPending
• Determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with ICIs to subjects with advanced solid tumors• Evaluate preliminary efficacy of XL092 when…